Financials in USD. Standardized financial statements.
A compact view of how Upstream Bio, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue? | $2.85M | $2.37M | $2.38M | $1.21M |
| Revenue Growth? | +20.4% | -0.4% | +96.4% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 |
| Gross Profit? | $2.85M | $2.37M | $2.38M | $1.21M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $163.22M | $80.13M | $42.49M | $25.12M |
| Operating Income? | -$160.36M | -$77.76M | -$40.11M | -$23.91M |
| EBITDA? | -$160.17M | -$77.67M | -$40.05M | -$23.90M |
| Income Before Tax | -$143.44M | -$62.81M | -$20.54M | -$23.87M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income? | -$143.44M | -$62.81M | -$20.54M | -$23.87M |
| EPS? | $-2.66 | $-1.49 | $-1.05 | $-0.66 |
| Diluted EPS? | $-2.66 | $-1.49 | $-1.05 | $-0.66 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality